Cipla gets approval to market Afrezza insulin inhalation powder in India

Q: How long will it take to read this news story?

The story "Cipla gets approval to market Afrezza insulin inhalation powder in India" has 327 words across 13 sentences, which will take approximately 2 - 3 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Cipla gets approval to market Afrezza insulin inhalation powder in India" was covered 18 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 277 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #24354695</li><li>URL: https://beamstart.com/news/cipla-gets-approval-to-market-17339250833066</li></ul>

Business Standard Logo Business Standard 18h ago

Cipla gets approval to market Afrezza insulin inhalation powder in India - Business Standard

Quick Summary:

Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder in India.

By bringing a game-changing, patient-centred solution to diabetes management in India, Cipla will make this drug accessible to all and empower millions to take control of their health with greater ease, the Mumbai-based company said in a statement.

Afrezza, a product created and manufactured by MannKind Corporation (MannKind) USA, is used to improve glycemic control in adult patients with diabetes mellitus.